U.S. flag

An official website of the United States government

NM_000186.4(CFH):c.3133+4C>G AND not specified

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Mar 21, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV004526766.2

Allele description [Variation Report for NM_000186.4(CFH):c.3133+4C>G]

NM_000186.4(CFH):c.3133+4C>G

Gene:
CFH:complement factor H [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1q31.3
Genomic location:
Preferred name:
NM_000186.4(CFH):c.3133+4C>G
HGVS:
  • NC_000001.11:g.196742055C>G
  • NG_007259.1:g.95045C>G
  • NM_000186.4:c.3133+4C>GMANE SELECT
  • LRG_47t1:c.3133+4C>G
  • LRG_47:g.95045C>G
  • NC_000001.10:g.196711185C>G
  • NM_000186.3:c.3133+4C>G
Links:
dbSNP: rs374729595
NCBI 1000 Genomes Browser:
rs374729595
Molecular consequence:
  • NM_000186.4:c.3133+4C>G - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV005039294Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Mar 21, 2024)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, et al.

J Am Soc Nephrol. 2019 Dec;30(12):2449-2463. doi: 10.1681/ASN.2019040331. Epub 2019 Oct 1.

PubMed [citation]
PMID:
31575699
PMCID:
PMC6900783

Genetic Risk in Families with Age-Related Macular Degeneration.

de Breuk A, Lechanteur YTE, Heesterbeek TJ, Fauser S, Klaver CCW, Hoyng CB, den Hollander AI.

Ophthalmol Sci. 2021 Dec;1(4):100087. doi: 10.1016/j.xops.2021.100087.

PubMed [citation]
PMID:
36246952
PMCID:
PMC9562327

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV005039294.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

Variant summary: CFH c.3133+4C>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Two predict the variant weakens a 5' donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00028 in 251412 control chromosomes. c.3133+4C>G has been reported in the literature in at least one compound heterozygous individual affected with atypical hemolytic uremic syndrome (e.g. Zuber_2019) and an individual affected with age-related macular degeneration (e.g. deBreuk_2021). These reports do not provide unequivocal conclusions about association of the variant with CFH-Related Disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 31575699, 36246952). ClinVar contains an entry for this variant (Variation ID: 598661). Based on the evidence outlined above, the variant was classified as uncertain significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 16, 2025